Loading clinical trials...
Loading clinical trials...
Phase II Randomized Controlled Trial Of Dendritic Cell + Cytokine-Induced Killer Cell Immunotherapy With S-1 Versus S-1 Alone As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma Patients
Conditions
Interventions
Dendritic cell + Cytokine-induced killer cell (DC+CIK) immunotherapy
Tegafur Only Product
Locations
1
Malaysia
Clinical Oncology Department, Ummc
Petaling Jaya, Kuala Lumpur, Malaysia
Start Date
January 3, 2023
Primary Completion Date
December 1, 2024
Completion Date
June 1, 2025
Last Updated
January 10, 2024
NCT05720117
NCT06898450
NCT05098132
NCT05719558
NCT04657068
NCT07477743
Lead Sponsor
University of Malaya
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions